SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001193125-23-296814
Filing Date
2023-12-15
Accepted
2023-12-15 17:29:30
Documents
15
Period of Report
2023-12-14
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K d50500d8k.htm   iXBRL 8-K 29441
2 EX-1.1 d50500dex11.htm EX-1.1 200104
3 EX-5.1 d50500dex51.htm EX-5.1 8823
7 GRAPHIC g50500img1.jpg GRAPHIC 3893
  Complete submission text file 0001193125-23-296814.txt   427448

Data Files

Seq Description Document Type Size
4 XBRL TAXONOMY EXTENSION SCHEMA sndx-20231214.xsd EX-101.SCH 2848
5 XBRL TAXONOMY EXTENSION LABEL LINKBASE sndx-20231214_lab.xml EX-101.LAB 18758
6 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE sndx-20231214_pre.xml EX-101.PRE 11709
9 EXTRACTED XBRL INSTANCE DOCUMENT d50500d8k_htm.xml XML 3497
Mailing Address 35 GATEHOUSE DRIVE BUILDING D, FLOOR 3 WALTHAM MA 02451
Business Address 35 GATEHOUSE DRIVE BUILDING D, FLOOR 3 WALTHAM MA 02451 781-419-1400
Syndax Pharmaceuticals Inc (Filer) CIK: 0001395937 (see all company filings)

IRS No.: 320162505 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-37708 | Film No.: 231491492
SIC: 2834 Pharmaceutical Preparations